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Crystal Structure of Carnitine Acetyltransferase
and Implications for the Catalytic Mechanism
and Fatty Acid Transport
been linked to many serious, even fatal human diseases.
Inherited recessive defects of CPT-I and CPT-II can give
rise to hypoketonemia and hypoglycemia, with severely
reduced blood glucose levels (McGarry and Brown,
1997; Ramsay et al., 2001). CPT-II deficiency is the most
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common cause of abnormal lipid metabolism in skeletal
Summary muscle, including muscle pain and myoglobinuria (Di-
Mauro and Melis-DiMauro, 1973). Both single-point mu-
Carnitine acyltransferases have crucial roles in the tations and insertions/deletions in these genes have
transport of fatty acids for -oxidation. Dysregulation been observed to produce the clinical phenotype. Inher-
of these enzymes can lead to serious diseases in hu- ited deficiency in CRAT activity can lead to serious neu-
mans, and they are targets for therapeutic develop- rological and heart problems, and patients suffering
ment against diabetes. We report the crystal struc- from Alzheimer’s disease also have reduced CRAT activ-
tures of murine carnitine acetyltransferase (CRAT), ity (Brunner et al., 1997).
alone and in complex with its substrate carnitine or Carnitine acyltransferases are promising targets for
CoA. The structure contains two domains. Surpris- the development of therapeutic agents against several
ingly, these two domains share the same backbone human diseases. Inhibitors of L-CPT-I, an isoform of
fold, which is also similar to that of chloramphenicol CPT-I that is mostly expressed in liver, kidney, and fibro-
acetyltransferase and dihydrolipoyl transacetylase. blasts, are efficacious for the treatment of non-insulin-
The active site is located at the interface between the dependent diabetes mellitus (NIDDM) (Anderson, 1998;
two domains. Carnitine and CoA are bound in deep Giannessi et al., 2001; Ramsay et al., 2001; Wagman
channels in the enzyme, on opposite sides of the cata- and Nuss, 2001), where disrupted glucose levels are
lytic His343 residue. The structural information pro- caused at least in part by increased fatty acid oxidation.
vides a molecular basis for understanding the catalysis A covalent inhibitor of L-CPT-I, etomoxir, can lower
by carnitine acyltransferases and for designing their blood glucose levels in diabetic animals and humans,
inhibitors. Specifically, our structural information sug- demonstrating the feasibility of this type of inhibitors.
gests that the substrate carnitine may assist the catal- The clinical applications of such irreversible inhibitors
ysis by stabilizing the oxyanion in the reaction interme- are unfortunately severely limited by their toxic side ef-
diate. fects. The design and development of new, reversible
inhibitors of L-CPT-I has so far been a rather challenging
Introduction process (Anderson, 1998), and better understanding of
the structure and function of these enzymes is needed.
Carnitine acyltransferases catalyze the exchange of acyl However, currently there is no structural information
groups between carnitine and coenzyme A (CoA) (Bieber, on any of these transferases. Crystals of human CRAT
1988; Kerner and Hoppel, 2000; McGarry and Brown, have recently been reported (Lian et al., 2002). Moreover,
1997; Ramsay et al., 2001). These enzymes include car- there is no recognizable sequence homology between
nitine acetyltransferase (CRAT, also known as CAT), car- these enzymes and other proteins in the database. To
nitine octanoyltransferase (COT), and carnitine palmi-
understand the molecular mechanism for the catalysis
toyltransferase (CPT), with substrate preferences for
by this important family of enzymes and to provide a
short chain, medium chain, and long chain fatty acids,
structural basis for the identification of their inhibitors,respectively. These enzymes generally contain about
we have determined the crystal structure of mouse600 residues, with molecular weights of about 70 kDa
CRAT, alone and in complex with the substrate carnitine(Figure 1).
or CoA, at up to 1.8 A˚ resolution. The amino acid se-The carnitine acyltransferases have important biologi-
quences of the various carnitine acyltransferases arecal functions. CPT-I and CPT-II are crucial for the
significantly conserved among the eukaryotes (Figure-oxidation of long chain fatty acids in the mitochondria,
1), with murine CRAT sharing about 35% amino acidby facilitating their transport across the mitochondrial
sequence identity to the other enzymes. Our structuralmembrane (McGarry and Brown, 1997; Ramsay et al.,
observations on CRAT should therefore be generally2001). The activity of CPT-I is inhibited by malonyl-CoA,
applicable to this entire family of enzymes.a crucial regulatory mechanism for fatty acid oxidation
(Abu-Elheiga et al., 2001). CRAT may be involved in the
Results and Discussiontransport of acetyl-CoA across intracellular membranes,
in maintaining the acetyl-CoA:CoA balance, and in the
Structure Determinationexcretion of excess or harmful acyl molecules as acylc-
The crystal structure of the free enzyme of mouse CRATarnitines (Bieber, 1988; Ramsay et al., 2001). CRAT activ-
was determined at 1.8 A˚ resolution by the selenome-ity may also be required for progression through G1 to
thionyl single-wavelength anomalous diffraction (SAD)the S phase of the cell cycle (Brunner et al., 1997).
Mutation or dysregulation of these enzymes have method (Hendrickson, 1991). There are two molecules
of the protein in the crystallographic asymmetric unit,
and each molecule contains 21 methionine residues (ex-*Correspondence: tong@como.bio.columbia.edu
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Figure 1. Sequence Alignment of Mouse Carnitine Acetyltransferase (CRAT) and Human Liver- and Muscle-Type Carnitine Palmitoyltransferase
I (L-CPT-I and M-CPT-I).
The secondary structure elements in the CRAT structure are labeled (S.S.). Residues shown in green are in the core of the protein, with less
than 25% exposed surface area. Residues in the carnitine (C), CoA (A), and fatty acid (F) binding pockets are also indicated. The residue
numbers are for CRAT. An additional 140 residues at the N terminus of L-CPT-I and M-CPT-I are not shown. A dash represents a residue
that is identical to that in CRAT, while a dot represents a deletion.
cluding the initiator Met). A total of 40 Se sites were The molecules in the asymmetric unit of these crystals
have essentially the same conformation, with rms dis-located based on the anomalous differences, and our
structural analysis showed that the Met residue near the tance of 0.34 A˚ for 587 equivalent C atoms. The con-
tacts among the non-crystallographically related andN terminus of each protein molecule is disordered. This
Met residue is present only in the recombinant protein, the crystallographically related dimers in these crystals
are generally weak and hydrophilic in nature. The proteinintroduced as a part of the His-tag by the expression
vector. The N-terminal His-tag is disordered in the migrates as monomers on gel filtration columns (data
not shown). The structural observations are consistentcrystal.
To determine the binding mode of the substrate carni- with biochemical data suggesting that the protein is
monomeric in solution (Ramsay et al., 2001).tine or CoA, we produced crystals of mouse CRAT in
the presence of these compounds. The subsequent
structural analysis at 1.9 A˚ resolution defined the binding Overall Structure of CRAT
The crystal structure of the free enzyme of mouse CRATmode of carnitine in the active site, but showed the
binding of oxidized CoA to the “wrong” region of the has been determined at 1.8 A˚ resolution. The current
atomic model contains residues 30–625 for each of theactive site. In these CoA crystals, the thiol of CoA was
oxidized to a sulfonic acid, even in the presence of two molecules in the asymmetric unit, which essentially
corresponds to the full-length, mature form of this en-10 mM DTT in the crystallization solution. The sulfonic
group of oxidized CoA is bound in the pocket that recog- zyme. All the residues except Ile116 are located in fa-
vored regions of the Ramachandran plot. Ile116 is thenizes the carboxylate group of carnitine, supporting the
preference for a negatively charged group in that pocket. second residue in a type II reverse turn, and its main
chain conformation is clearly defined by the electronThe ADP portion on the other end of the CoA molecule
is disordered. density. The crystallographic information is summarized
in Table 1.The binding mode of CoA was determined instead
from an X-ray diffraction data set on a free enzyme The structure of CRAT contains 16  strands (1–16)
and 20  helices (1–20) and can be divided into twocrystal soaked with acetyl-CoA. The crystal suffered
serious damage during the soaking process, and the domains (Figure 2A). The C domain contains a six-
stranded mixed  sheet, together with eleven  helices.quality of the diffraction data set is rather poor (Table
1). Consequently, the R factor for the atomic model is Residues in this domain include the C-terminal 1/3 of
the protein (residues 407–626) as well as residues 30–95high (Table 1). Nonetheless, the binding mode of CoA
is clearly defined by the electron density map. at the N terminus, which contribute four  helices to this
Crystal Structure of Carnitine Acetyltransferase
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Table 1. Summary of Crystallographic Information
Substrate — Carnitine CoA
Maximum resolution (A˚) 1.8 1.9 2.3
Number of observations 749,015 347,562 135,285
Rmerge (%)1 4.4 (12.0) 5.7 (17.4) 8.8 (26.1)
I/I 19.1 (6.2) 19.6 (6.7) 9.5 (3.2)
Resolution range used for refinement 30–1.8 A˚ 20–1.9 A˚ 30–2.3 A˚
Number of reflections2 235,313 105,409 53,398
Completeness (%) 97 (94) 97 (93) 85 (75)
R factor (%)3 18.8 20.1 27.0
Free R factor (%) 21.7 24.1 36.3
rms deviation in bond lengths (A˚) 0.005 0.006 0.009
rms deviation in bond angles () 1.2 1.2 1.3
1 Rmerge  
h

i
|Ihi   Ih|/
h

i
|Ihi. The numbers in parentheses are for the highest resolution shell.
2 The number for the free enzyme includes both Friedel pairs.
3 R  
h
|Foh  Fch|/
h
Foh.
domain and interact with a segment between 17 and the long connection between the N and the C domains
(Figure 2A).13 (Figure 2B). One face of the  sheet in this domain
is covered by the  helices, whereas part of the other The N domain contains an eight-stranded mixed 
sheet, which is covered on both sides by eight  helicesface of this sheet contacts the N domain of the structure
(residues 96–385). Helix 13, residues 386–487, forms (Figure 2C). This eight-stranded  sheet is formed by
Figure 2. Structure of CRAT
(A) Stereo diagram showing a schematic representation of the structure of CRAT. The  strands and  helices are labeled, and the catalytic
His343 residue is shown in red. The binding modes of carnitine (in green) and CoA (in brown) are also indicated.
(B) Structure of the C domain of CRAT.
(C) Structure of the N domain of CRAT, in the same orientation as the C domain.
(D) Structure of the monomer of chloramphenicol acetyltransferase CAT, viewed in the same orientation as (B). The secondary structure
elements are named according to Leslie et al., 1988. The catalytic His195 residue is shown in red.
(E) Structure of two monomers in the trimer of CAT. The active site is located at the interface between the two monomers. The substrates
CoA and chloramphenicol (Cm) are also shown and labeled. Produced with Ribbons (Carson, 1987).
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flanking the central six-stranded sheet with one extra  acid residues each, larger than the sizes of CAT and
E2pCD (about 220 residues). As a result, the two do-strand on each of its edges (Figure 2C). Interestingly,
one of these extra  strands actually comes from the C mains in CRAT have significant insertions in several of
the surface loops as compared to CAT or E2pCD (Fig-domain. Part of the 13–15 crossover connection in
the C domain forms a  strand (14) (Figure 2B), and ures 2B–2D). These insertions form additional interac-
tions within the domains, for example those betweenthis strand is hydrogen-bonded to 1 in an anti-parallel
fashion in the N domain (Figure 2C). The N domain also the 18–19 insertion and helices 2–4 in the C domain
(Figure 2B). In the N domain, the 8–10 and 11 inser-contains a pair of  strands (2 and 3) on the surface,
helping enclose one end of the  sheet. tions cover the face of the  sheet (Figure 2C) that would
be shielded from solvent by the third monomer in theSurprisingly, the N and C domains share very similar
polypeptide backbone folds (Figures 2B and 2C), de- trimers of CAT and E2pCD.
spite the lack of any recognizable amino acid sequence
homology between them. This structural homology is The Active Site of CRAT
limited to the core of the two domains, including the Previous biochemical, kinetic, and mutagenesis studies
central six  strands of the  sheet and three  helices have identified a histidine residue, equivalent to His343
closely associated with it (6, 7, and 12 in the N in CRAT (Figure 1), as the catalytic residue for the carni-
domain). A total of 71 Cpositions can be superimposed tine acyltransferases (McGarry and Brown, 1997; Ram-
to within 3.5 A˚ of each other between the two domains, say et al., 2001). Our structural analysis confirms the
and the rms distance for these equivalent atoms is 2.0 A˚. functional importance of the His343 residue, in the con-
However, there are only three pairs of identical residues nection between 8 and 12 in the N domain (Figure
(4%) among these structurally aligned positions, under- 2C). It is located at the same position as His195 in CAT
scoring the lack of amino acid sequence conservation (Figure 2D) and His610 in E2pCD, the catalytic residues
between the two domains. of these enzymes (Leslie et al., 1988; Mattevi et al., 1992).
As in CAT and E2pCD, the side chain of the His343
residue in CRAT is held in an unusual conformation, suchUnexpected Structural Conservation with
that the N	1 ring nitrogen in the side chain is hydrogen-Chloramphenicol Aetyltransferase (CAT) and
bonded to the carbonyl oxygen in its main chain.Dihydrolipoyl Transacetylase (E2pCD)
The active site of CRAT is located deep in the enzyme,Comparisons with the protein structure database, per-
at the interface between the N and C domains (Figureformed with the program Dali (Holm and Sander, 1993),
2A). The His343 residue can be reached by two separaterevealed that the N and the C domains of CRAT have
channels, of 15–18 A˚ depth each, from opposite sidessimilar backbone folds as that of chloramphenicol ace-
of the protein (Figure 2A). One of these channels is usedtyltransferase (CAT) (Figure 2D) (Leslie et al., 1988) and
for the binding of the CoA substrate, whereas the otherthe catalytic domain of dihydrolipoyl transacetylase
is for binding carnitine. While the overall arrangement(E2pCD) (Mattevi et al., 1992). Both of these enzymes
of the active site is similar to that in CAT (Figure 2E) andcatalyze the transfer of an acetyl group from acetyl-CoA
E2pCD (Leslie et al., 1988; Mattevi et al., 1993), thereto an organic substrate. In addition, E2p forms the cubic
are significant differences in the binding modes of thecore of the pyruvate dehydrogenase multienzyme com-
substrates, especially CoA, as well as the catalyticplex (Mattevi et al., 1992). A total of 161 out of 213 C
mechanism, between CRAT and these other enzymesatoms in CAT can be superimposed with the equivalent
(see below).atoms in the C domain of CRAT, and the rms distance of
these atoms is 3.7 A˚. The amino acid sequence identity
among these structurally equivalent residues is however The Carnitine Binding Site
The crystal structure of CRAT in complex with the sub-only 9%. Similar observations are made when the CAT
structure is aligned with the N domain of CRAT or when strate carnitine has been determined at 1.9 A˚ resolution
(Table 1). The binding mode of carnitine is clearly definedthe structure of E2pCD is used for comparison.
Most remarkably, the structural conservation between by the crystallographic analysis (Figure 3A). We have
also collected X-ray diffraction data on crystals of CRATCRAT and CAT or E2pCD extends beyond the similarity
in their backbone folds. The organization of the two grown in the presence acetylcarnitine, the product of
the reaction. The subsequent crystallographic analysis,domains of CRAT is similar to that of two monomers in
the trimers of CAT and E2pCD (Figure 2E). The rotational at 1.9 A˚ resolution, showed however the presence of
only carnitine in the active site (data not shown). Thisrelationship between the N and C domains of CRAT is
118, close to a 3-fold rotation. Both CAT and E2pCD suggests that the acetylcarnitine has been hydrolyzed
to carnitine during the crystallization process, and thisfunction as trimers, and the active site of the enzymes
is located at the interface between a pair of monomers hydrolysis may possibly be catalyzed by the enzyme
itself.in the trimer (Figure 2E) (Leslie et al., 1988; Mattevi et
al., 1992). It appears that CRAT may have evolved by Carnitine is bound in a partially folded conformation,
with its carboxyl group pointed in the opposite directiongene duplication of a single-domain enzyme (such as
E2p or CAT), and the resulting two-domain enzyme has from the hydroxyl group (Figure 3A). This bound confor-
mation corresponds to one of the favored rotamers ofthe same function as a homo-trimer of the single-domain
enzymes. this compound in solution, as indicated by NMR studies
of free cartinine in aqueous solution (Colucci et al., 1986).The amino acid sequences of CRAT have diverged
significantly from those of CAT and E2pCD. In addition, The carnitine binding site is formed by the  sheet
(strands 11–14) in the C domain and residues in 5–1the N and C domains of CRAT contain about 300 amino
Crystal Structure of Carnitine Acetyltransferase
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Figure 3. The Carnitine Binding Site of CRAT
(A) Final 2Fo–Fc electron density map for carnitine at 1.9 A˚ resolution. The contour level is at 1. Produced with Setor (Evans, 1993).
(B) Stereo diagram showing the carnitine binding site of CRAT. The side chain of the catalytic His343 residue is shown in red, and carnitine
is shown in green. A water molecule that mediates carnitine binding is shown as a red sphere and labeled W. Produced with Ribbons (Carson,
1987).
(C) Molecular surface of CRAT in the region of the carnitine binding site. Produced with Grasp (Nicholls et al., 1991).
(D) Schematic drawing of the interactions between carnitine and CRAT. Hydrogen-bonding interactions are shown as thick dashed lines, and
the electrostatic interaction between the carboxylate group and Arg518 is shown as the thin dashed line.
and 8–12 in the N domain (Figure 3B). One face of over the aromatic ring of the side chain of Phe566 (14),
with a separation of about 3.6 A˚ (Figure 3B). It is alsothe carnitine molecule is exposed to the solvent in the
bound state (Figure 3C). The 3-hydroxyl group on carni- close to the side chain of Ser552 (13) and Val569 (14–
15 loop). However, there are no negatively chargedtine forms a hydrogen bond with the side chain N
2
atom of the catalytic His343 residue (Figure 3D), which residues in the immediate vicinity of this group to bal-
ance its positive charge. Our structural analysis sug-has implications for the catalytic mechanism of this fam-
ily of enzymes (see below). The structural analysis dem- gests this positive charge may be important for the cata-
lytic activity of the enzyme (see below).onstrates that the catalysis is stereo-specific, as the
other stereo-isomer of the hydroxyl group cannot main- Most of the residues in this binding site are highly
conserved among the carnitine acyltransferases (Figuretain the same interactions with the enzyme.
The carboxylate group of carnitine has electrostatic 1). Our structural observations on the binding interac-
tions of carnitine are supported by a large body of exper-interactions with the side chain guanidinium group of
Arg518 (from helix 18), with a distance of about 4 A˚, imental data on mutants of these enzymes, as well as by
the natural variations in the sequences of these enzymesas well as a network of hydrogen-bonding interactions
(Figures 3B and 3D). One of the carboxylic oxygen atoms (McGarry and Brown, 1997; Ramsay et al., 2001). For
example, Thr465 and Arg518 have important roles in theis hydrogen-bonded to the side chain hydroxyls of
Tyr452 and Ser454 (11), whereas the other is hydrogen- recognition of the carboxylate group of carnitine (Figure
3D) and are conserved among all carnitine acyltransfer-bonded to the side chain hydroxyl of Thr465 (12) and
a water molecule. The tetrahedral coordination of this ases (Figure 1). However, these two residues are not
conserved in the homologous choline acetyltransfer-water is completed by three ligands from the enzyme,
the N
1 atom of Trp102 (5), the O atom of Tyr107 (5), ases, because the choline substrate lacks a carboxylate
group at this position (Cronin, 1997a). Moreover, theand the O
2 atom of Glu347 (8–12 loop), which also
shield it from the solvent (Figure 3B). Arg→Asn mutation in bovine COT led to a 1650-fold
increase in the Km for carnitine, while having little effectsThe trimethylammonium group of carnitine is situated
Cell
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Figure 4. The CoA Binding Site of CRAT
(A) Final 2Fo–Fc electron density map for CoA at 2.3 A˚ resolution. The contour level is at 1. Produced with Setor (Evans, 1993).
(B) Stereo diagram showing the CoA binding site of CRAT. The CoA molecule is shown in brown. Produced with Ribbons (Carson, 1987).
(C) Overlap of the binding modes of CoA to CRAT (in brown) and CAT (in cyan).
(D) Molecular surface of CRAT in the region of the CoA binding site. (C and D) produced with Grasp (Nicholls et al., 1991).
on the Km for CoA or the kcat of the enzyme (Cronin, interactions with the carboxylate of carnitine (Figure 3D).
Outside the active site, conformational differences are1997a). Our structure shows an indirect, electrostatic
interaction between this residue and the carboxylate observed for several regions on the surface of the struc-
ture. In addition, there are small rigid body movementsgroup (Figure 3D), rather than a direct binding via hydro-
gen-bonding interactions. of the domains relative to each other. However, these
changes are more likely due to flexibility in the enzymeIn the binding site for the trimethylammonium group,
Ser552 is the first residue of the strictly conserved STS or differences in crystal packing, and they have only
minor impact on the active site region.motif among these acyltransferases (Figure 1). Mutation
of this Ser residue to Ala in bovine COT produced a 17-
fold increase in the Km for carnitine, but only a 2-fold The CoA Binding Site
The crystal structure of CRAT in complex with the sub-decrease in the kcat of the enzyme (Cronin, 1997b), con-
sistent with our structural observations (Figure 3B). In- strate CoA has been determined at 2.3 A˚ resolution
(Table 1). To obtain this structure, X-ray diffraction dataterestingly, mutation of the Thr residue in this motif to
Ala produced a 90-fold increase in the Km for carnitine, were collected on a crystal of the free enzyme of CRAT
that was soaked overnight with 1.5 mM acetyl-CoA. Theeven though the side chain of this residue is pointed
away from the active site. Detailed structural analysis crystal suffered serious damage during the soak, giving
rise to higher R factors for the diffraction data and theshowed that the side chain hydroxyl of the Thr residue
is hydrogen-bonded to the main chain carbonyl oxygen atomic model (Table 1). Nonetheless, the current data
set is of sufficient quality to clearly define the bindingof Tyr452 in strand 11 (Figure 3B), and the mutation
may have disrupted the conformation of the enzyme in mode of the substrate (Figure 4A). It also indicates that
the compound bound in the active site is actually CoAthis area.
CRAT has a preformed binding site for the substrate (Figure 4A). This suggests that acetyl-CoA has been
hydrolyzed to CoA during the overnight soaking pro-carnitine. The only significant conformational difference
in the active site between the free enzyme and the carni- cess. Therefore, it appears that CRAT may be able to
catalyze the hydrolysis of both acetylcarnitine and ace-tine complex is in the side chain of Ser454, which adopts
a different rotamer to have better hydrogen-bonding tyl-CoA. We have also obtained cocrystals of the en-
Crystal Structure of Carnitine Acetyltransferase
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Figure 5. The Possible Fatty Acid Binding
Site of Carnitine Acyltransferases
A model for the binding mode of acetylcarni-
tine is shown. The acetyl group points toward
a hydrophobic pocket that could also be used
to bind long chain acyl groups.
zyme with CoA. The subsequent crystallographic analy- site for the pantothenic arm of CoA, conserved residues
Asp430 and Glu453 are directly hydrogen-bonded tosis revealed partial occupancy of the binding site.
However, the binding mode of CoA confirms that ob- each other (Figure 4B). Mutation of either residue can
reduce the activity of the enzyme (Ramsay et al., 2001).served from the soaked crystal.
The CoA binding site is on the opposite side of the
His343 side chain from the carnitine binding site (Figure The Fatty Acid Binding Site
Our structures of the substrate complexes of CRAT also2A). A special feature of the  sheet in the C domain is
that the neighboring parallel strands 11 and 13 are help to reveal the possible binding site for the hydrocar-
bon groups of long chain fatty acids in the CPTs. Thesplayed apart from each other at the C-terminal end
(Figure 4B), which is also observed in CAT and E2pCD. acetyl group of acetylcarnitine, modeled based on the
structure of the carnitine complex, points toward a hy-This creates an opening between the two strands and
allows the pantothenic arm of CoA to thread through it drophobic pocket that is enclosed by the intersection
of the two  sheets in the enzyme (strands 1 and 8to reach the active site (Figure 4B). In the active site,
the thiol group forms a hydrogen bond with the side in the N domain, strands 13 and 14 in the C domain)
and helix 12 (Figure 5). In CRAT, this pocket is partlychain N
2 atom of the catalytic His343 residue.
The CoA molecule is bound in the fully extended, filled by the side chain of Met564, coming from strand
14 (Figure 5). The equivalent residue in the CPTs is alinear conformation (Figure 4B). The adenine base at
one end of the molecule is about 25 A˚ from the thiol glycine (Figure 1), which should make it possible for the
hydrocarbon groups of the long chain fatty acid to bindgroup at the other. This binding mode is in sharp contrast
to the binding of CoA to CAT and E2pCD, where a folded in this pocket. The mutation of this Gly to Glu can cause
L-CPT-I deficiency in patients (Ramsay et al., 2001).conformation of CoA is observed (Leslie et al., 1988;
Mattevi et al., 1993). A comparison of the two binding Additional differences in the amino acid sequences of
CRAT and CPTs, for example in the 5–1 region (Fig-modes showed that the pantotheine portion has similar
conformations, but the ADP portion has large differ- ures 1 and 3B), may also contribute to substrate binding
in the CPTs.ences (Figure 4C). The adenine bases are separated by
about 14 A˚ in the two binding conformations. In CAT
and E2pCD, the N1 and N6 atoms of the adenine base Implications for the Catalytic Mechanism:
Substrate-Assisted Catalysisare hydrogen-bonded to the main chain amide and car-
bonyl of residues near the end of strand I (Figure 2E). Our structures of the free enzyme and the substrate
complexes of CRAT convincingly demonstrate the cata-In CRAT, the equivalent residue, at the end of strand
15, is Pro580 (Figure 4B), which would abolish the type lytic mechanism of this family of enzymes (Figure 6).
The His residue in the active site acts as a general baseof interactions observed in CAT and E2pCD as it not
only eliminates the hydrogen bond but also introduces in the catalysis (McGarry and Brown, 1997; Ramsay et
al., 2001). It extracts the proton from the 3-hydroxylsteric clash with the adenine base. In our structure, the
adenine base lies on the surface of the enzyme (Figures group of carnitine or the thiol group of CoA, depending
on the direction of the reaction. In our structures of the5B and 5D) and there appears to be no specific recogni-
tion of its N1 or N6 atoms. carnitine and CoA complexes, the reactive groups of
both substrates are directly hydrogen-bonded to theResidues in the CoA binding pocket are generally con-
served among the carnitine acyltransferases (Figure 1). His343 side chain. So the substrates are optimally posi-
tioned in our structures for the catalysis to happen. TheThese include Lys419 and Lys423, which recognize the
3-phosphate group of CoA (Figure 4B). In the binding activated hydroxyl or thiol group can then directly attack
Cell
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Figure 6. The Catalytic Mechanism of Carnitine Acyltransferases
The catalytic His343 residue can extract the proton from either carnitine or CoA. The oxyanion in the tetrahedral intermediate is stabilized by
interactions with carnitine and the side chain hydroxyl of Ser554.
the carbonyl carbon in acyl-CoA or acylcarnintine, and neered mutations on these enzymes. A large number of
natural mutations in these enzymes have been de-the reaction proceeds without the formation of an acyl-
scribed, leading to various disease states (McGarry andenzyme intermediate.
Brown, 1997; Ramsay et al., 2001). These disease-caus-It is also clear from the mechanism and our structures
ing mutations, as well as the engineered mutations, canthat if only acylcarnitine or acyl-CoA is bound in the
be roughly divided into two categories, depending onactive site, a water molecule binds in the opposite chan-
whether they can affect (directly or indirectly) the activenel of the active site and can become the receptor for
site of the enzyme. Mutations that directly affect thethe acyl groups. Therefore, these transferases can also
binding of carnitine or CoA have already been discussedcatalyze the simple hydrolysis of acylcarnitine or acyl-
here. The S113L mutation in CPT-II, one of the mostCoA, as we observed in our crystallization experiments.
common natural mutations in that enzyme, may indi-This futile hydrolysis is probably not a significant reac-
rectly affect the active site. The equivalent residue intion in vivo, as the active site of the enzyme is likely to
CRAT is Ser99, located in helix 5 (Figure 1), whichbe occupied by its two substrates.
also contains residues (Trp102 and Tyr107) that haveStructural analysis and modeling studies suggest that
important roles in carnitine binding (Figure 3B). How-the trimethylammonium group of carnitine may play an
ever, the side chain of this residue does not show strongimportant role in the catalysis by these acyltransferases,
interactions with other residues in the enzyme, whichby stabilizing the oxyanion in the tetrahedral intermedi-
may be consistent with the fact the S113L mutationate of the reaction (Figure 6). This suggests that carnitine
creates only mild effects (Ramsay et al., 2001).acyltransferases may be an example of substrate-assisted
Mutations in the second category may affect the sta-catalysis (Dall’Acqua and Carter, 2000). Our structure
bility or the production of the enzyme, as some of thesemodel for the intermediate would place the oxyanion at
mutants are known to have reduced cellular levels butabout 3 A˚ distance to the trimethylammonium group
with normal kinetic parameters (McGarry and Brown,of carnitine, suggesting strong, favorable interactions
1997; Ramsay et al., 2001). A possible example of suchbetween the two charges (Figure 6). This is supported
a mutation is P50H in CPT-II, equivalent to Pro36 inby the observation that the positive charge of carnitine
CRAT and the first proline in the highly conservedis not critical for its binding, but is absolutely required
LPXLPVP motif among these enzymes (Figure 1). Thefor catalysis (Saeed et al., 1993). A carnitine analog,
residue is located far from the active site, in the linkerreplacing the trimethylammonium group with the neutral
between helices 1 and 2 (Figure 2A). The mutationt-butyl group, is not a substrate of the enzyme but can
has only mild clinical effects (Ramsay et al., 2001), andcompete with carnitine for binding to the active site.
the side chain of Pro36 is mostly exposed to the solvent
Based on our model for the tetrahedral intermediate,
(Figure 1).
the oxyanion is also within 3 A˚ of the side chain hydroxyl
For their important biological functions and as promis-
of Ser554 (Figure 6). Mutation of this Ser residue, in the ing targets for the development of therapeutic agents
STS motif described earlier, produced a 10-fold de- against NIDDM and other human diseases, carnitine
crease in the kcat while having little impact on the Km for acyltransferases have received a significant amount of
carnitine (Cronin, 1997b). The equivalent Ser residue in attention over the past years (Anderson, 1998; Giannessi
CAT and E2pCD has also been identified as the oxyanion et al., 2001; McGarry and Brown, 1997; Ramsay et al.,
hole of those enzymes (Hendle et al., 1995; Lewendon 2001; Wagman and Nuss, 2001). Our structural informa-
et al., 1990). However, the small effect of the S554A tion on these enzymes provides the foundation for un-
mutation on the catalysis by COT also supports the derstanding their catalytic mechanism and for struc-
functional role of the carnitine substrate itself in stabiliz- tural-based design and optimization of their inhibitors.
ing the transition state of this reaction.
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